MTAP and cancer: Therapeutic targeting of PRMT5 in homozygous MTAP‐deleted cancer cells has thus been considered a promising strategy to selectively killed cancer cells, which predicated on the presence of exceedingly high MTA levels in MTAP‐deleted cancer cells compared to MTAP‐intact tissues.